Levamisole: As Adjuvant to Cyclic Chemotherapy in Breast Cancer

  • E. J. W. Stephens
  • H. F. Wood
  • B. Mason
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)


Sixty women under the age of 65 attending the Clinical Oncology Unit at Auckland Hospital, Auckland, New Zealand and who had symptomatic end-stage mammary carcinoma were invited to participate in this study after its nature and aims had been explained to them. Fifty-five patients were postmenopausal by natural or artificial means. Fifty-four of these women had failed to achieve a remission or had achieved and then lost a remission by a variety of hormonal manipulations both additive and ablative. A further six women were incorporated into this study as primary therapy because of the known absence of cellular oestrogen receptors or because of rapidly progressive visceral disease without knowledge of oestrogen receptor status. The 60 patients were treated between September 1975 and December 1976, the minimum follow-up being 15 months and the maximum 27 months at the time of reporting.


Partial Remission Oestrogen Receptor Status Infective Episode Auckland Hospital Enhance Cell Kill 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amery, W. K.: Overview of other controlled clinical data; an attempt at defining the future position of Levamisole in cancer therapy. Symposium of Immunotherapy of Malignant Disease. Vienna, 9–10 November 1976.Google Scholar
  2. 2.
    Hall, S. W. et al.: In: Control of neoplasia by modulation of the immune system. Chirigos, M. A. (ed.). New York: Raven Press 1976.Google Scholar
  3. 3.
    Hersh, E. M., Mavlight, G. M., Gutterman, J.: Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient. Med. Clin. North Am. 603, 623 (1976).Google Scholar
  4. 4.
    Hersh, E. M. et al.: Immunocompetence, immunodeficiency and prognosis in cancer. Ann. N.Y. Acad. Sci. 276, 386 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    Hortobagyi, G. N. et al.: In: Control of neoplasia by modulation of the immune system. Chirigos, M. A. (ed.). New York: Raven Press 1976.Google Scholar
  6. 6.
    Koelmeyer, T. D., Stephens, E. J. W.: Aminogluthethimide in end stage breast cancer. Clin. Oncol. (1978) (to be published).Google Scholar
  7. 7.
    Lods, J. C. et al.: Levamisole and bone marrow restoration after chemotherapy. Lancet 1976/I, 548.Google Scholar
  8. 8.
    Radov, L. A. et al.: Int. J. Cancer 17, 773 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    Rojas, A. F. et al.: Levamisole in advanced human breast cancer. Lancet 1976/I, 211.Google Scholar
  10. 10.
    Watkins, S. M.: Effects of surgery on lymphocyte transformation in patients with cancer. Clin. Exp. Immunol. 14, 69 (1973).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • E. J. W. Stephens
  • H. F. Wood
  • B. Mason

There are no affiliations available

Personalised recommendations